Seelos Therapeutics, Inc. (SEEL) stock soared 4.27% in the after-hours trading session at the price of $2.20 despite no fundamental reason. The last published news was the company’s participation in the upcoming investor conferences in September 2021. SEEL is a clinical-stage biopharmaceutical company. It discovers and develops novel therapeutics to treat patients dealing with central nervous system (CNS) disorders.
Participation in Investor Conferences in September 2021
On 9th September 2021, SEEL announced that it would present at the Cantor Virtual Global Healthcare Conference from 27th-30th September 2021. Chairman and CEO of the company, Raj Mehra, will host conference calls and participate in a fireside chat on 29th September 2021, at 10:00 am ET.
SEEL Appointed Margaret Dalesandro
On 2nd September 2021, SEEL published that it had appointed Margaret Dalesandro as the Board of Directors. As a proficient biopharmaceutical official, she has 30 years of experience in the development and commercialization of drugs. She worked at numerous senior management positions at ImClone Systems, Inc. In Portfolio and Alliance Management, she directed the successful development of ERBITUX (cetuximab), which contributed $6.5 billion in sales of ImClone in 2008.
She is currently the founder and president of Brecon Pharma Consulting LLC. Brecon Pharma is a full-service pharmaceutical and biotechnology consultancy that identifies and obtains critical information early in product development. CEO of SEEL, Raj Mehra, remarked that Dr. Margaret brought enormous drug development and commercialization experience to the company. As they advance with their late-stage clinical development, they expect meaningful contributions from her.
Senior Management Appointments
On 1st September 2021, SEEL published that it had promoted Anthony Marciano to Chief Communications Officer. The company had also promoted Michael Golembiewski to Chief Financial Officer. Both promotions became effective on 1st September 2021. Raj Mehra congratulated both of them on their senior promotions. He remarked that their senior management roles evidence their hard work and dedication to the company.
Mr. Golembiewski started his work with SEEL as Vice President of Finance in January 2019. Before this position, he served as the Vice President of Finance at Agile Therapeutics, Inc. He is a Certified Public Accountant and started his career with ImClone Systems Incorporated.
Mr. Marciano joined SEEL in August 2017 as a consultant and was allocated Head of Corporate Communications later in 2019. Mr. Marciano began his career at Leerink Partners as a healthcare-dedicated institutional equity salesman in 2000. He has a deep understanding of the investment banking process, placement of equity, and debt transactions.
